4D pharma plc announced that following the appointment of administrators on 24 June 2022, recruitment of new patients into ongoing clinical studies will be temporarily paused. The studies impacted are: the Phase I/II study of MRx0518, in combination with KEYTRUDA® (pembrolizumab), in patients with solid tumors. This study is currently in Part B and has met its primary efficacy endpoint early in the renal cell carcinoma group, as announced on 23 March 2022, having previously successfully completed Part A as announced on 11 May 2020; the Phase II clinical trial of MRx0518, in combination with BAVENCIO® (avelumab), in patients with urothelial carcinoma; the Phase I study of MRx0518 in patients with pancreatic cancer; the Phase I/II study of MRx-4DP0004 in patients with asthma.

Part A of this study was successfully completed as announced on 13 December 2021; and the Phase I study of MRx0005 or MRx0029 in patients with Parkinson's disease. 4D pharma is working with the administrators to enable an exit from administration as soon as possible and, in the event that the company does exit administration, currently plans to recommence recruitment so long as additional capital funding is secured. Further announcements will be made in due course.